This study found that amivantamab-chemotherapy (amiva-chemo) or amivantamab-lazertinib (a third-generation TKI)- chemotherapy (amiva-lazer-chemo) significantly improved PFS in patients with osimertinib-resistant EGFR-mutated NSCLC compared to chemotherapy (24). Here, EGFR is linked to non-small cell lung carcinoma.